share_log

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $144

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $144

巴克莱对Quest Diagnostics保持同等权重,将目标股价上调至144美元
Benzinga ·  04/25 14:36

Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and raises the price target from $138 to $144.

巴克莱分析师斯蒂芬妮·戴维斯维持Quest Diagnostics(纽约证券交易所代码:DGX)的权重相等,并将目标股价从138美元上调至144美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发